| Literature DB >> 30404930 |
Taylor K S Richter1,2, Tracy H Hazen1,2, Diana Lam3, Christian L Coles4, Jessica C Seidman5, Yaqi You3, Ellen K Silbergeld5, Claire M Fraser1,6, David A Rasko7,2.
Abstract
The stability of the Escherichia coli populations in the human gastrointestinal tract is not fully appreciated, and represents a significant knowledge gap regarding gastrointestinal community structure, as well as resistance to incoming pathogenic bacterial species and antibiotic treatment. The current study examines the genomic content of 240 Escherichia coli isolates from 30 children, aged 2 to 35 months old, in Tanzania. The E. coli strains were isolated from three time points spanning a six-month time period, with and without antibiotic treatment. The resulting isolates were sequenced, and the genomes compared. The findings in this study highlight the transient nature of E. coli strains in the gastrointestinal tract of these children, as during a six-month interval, no one individual contained phylogenomically related isolates at all three time points. While the majority of the isolates at any one time point were phylogenomically similar, most individuals did not contain phylogenomically similar isolates at more than two time points. Examination of global genome content, canonical E. coli virulence factors, multilocus sequence type, serotype, and antimicrobial resistance genes identified diversity even among phylogenomically similar strains. There was no apparent increase in the antimicrobial resistance gene content after antibiotic treatment. The examination of the E. coli from longitudinal samples from multiple children in Tanzania provides insight into the genomic diversity and population variability of resident E. coli within the rapidly changing environment of the gastrointestinal tract of these children.IMPORTANCE This study increases the number of resident Escherichia coli genome sequences, and explores E. coli diversity through longitudinal sampling. We investigate the genomes of E. coli isolated from human gastrointestinal tracts as part of an antibiotic treatment program among rural Tanzanian children. Phylogenomics demonstrates that resident E. coli are diverse, even within a single host. Though the E. coli isolates of the gastrointestinal community tend to be phylogenomically similar at a given time, they differed across the interrogated time points, demonstrating the variability of the members of the E. coli community in these subjects. Exposure to antibiotic treatment did not have an apparent impact on the E. coli community or the presence of resistance and virulence genes within E. coli genomes. The findings of this study highlight the variable nature of specific bacterial members of the human gastrointestinal tract.Entities:
Keywords: Escherichia colizzm321990; diversity; microbial genomics
Mesh:
Substances:
Year: 2018 PMID: 30404930 PMCID: PMC6222053 DOI: 10.1128/mSphere.00558-18
Source DB: PubMed Journal: mSphere ISSN: 2379-5042 Impact factor: 4.389
FIG 1Overall study design. The overall design of the study highlighting the sampling of up to three distinct colonies on three time points, one of which, termed the baseline, occurs prior to the administration of antibiotics in half of the subjects.
FIG 2Isolate metadata. Summary of metadata showing time point of isolation, treatment group, host sex, clinical presentation, and the identification of pathogenic markers for ETEC, EAEC, or EPEC pathotypes for each isolate by subject. Further details in Table S1.
FIG 3Phylogenomic analysis of E. coli isolates in study. A whole-genome phylogeny of the isolate sequences and reference E. coli and Shigella genomes (shown in black) highlighting examples of diversity among subject-specific isolates within and across time points. The scale bar indicates the approximate distance of 0.03 nucleotide substitutions per site. Nodes with bootstrap values of greater than 90 are marked with a circle. Examples of isolates from subjects that demonstrate the greatest (3_475_03) and least (4_203_08, 8_415_05, and 1_182_04) amount of diversity are highlighted: 3_475_03 in red, 4_203_08 in blue, 8_415_05 in green, and 1_182_04 in purple. The number of dots denotes the sample number from which the isolate was obtained. E. coli phylogroups are labeled. A full figure with all subjects is presented in Fig. S1.
Summary of isolate diversity within subject and within time points
| Subject | Treatment | Isolate | Resistance | Virulence | Phylogroup | MLST | Serotype | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of | No. of | No. of | Isolates | Similar | No. of | Similar | Similar | No. of | Similar | No. of | Similar | No. of | Similar | ||
| 1_110_08 | MDA | 9 | 5 | 5 | No | No | 5 | No | Yes | 3 | No | 3 | No | 5 | Yes |
| 1_176_05 | MDA | 8 | 4 | 4 | No | Yes | 4 | Yes | Yes | 2 | No | 3 | No | 4 | Yes |
| 1_182_04 | MDA | 9 | 3 | 5 | No | No | 3 | Yes | No | 2 | No | 3 | Yes | 3 | Yes |
| 1_250_04 | MDA | 7 | 3 | 2 | Yes | No | 3 | Yes | No | 3 | Yes | 3 | Yes | 3 | Yes |
| 1_392_07 | MDA | 8 | 4 | 5 | No | No | 4 | Yes | No | 3 | No | 4 | Yes | 4 | Yes |
| 3_020_07 | MDA | 8 | 4 | 4 | No | Yes | 4 | Yes | Yes | 3 | No | 4 | Yes | 4 | Yes |
| 3_073_06 | MDA | 7 | 5 | 5 | No | Yes | 4 | No | No | 3 | No | 5 | No | 5 | No |
| 3_105_05 | MDA | 9 | 7 | 6 | No | Yes | 7 | Yes | No | 2 | No | 7 | Yes | 7 | Yes |
| 3_267_03 | MDA | 7 | 6 | 6 | No | Yes | 6 | Yes | Yes | 3 | No | 6 | Yes | 6 | Yes |
| 3_373_03 | MDA | 9 | 4 | 4 | No | Yes | 3 | No | No | 1 | No | 3 | No | 4 | Yes |
| 3_475_03 | MDA | 6 | 6 | 5 | No | No | 6 | Yes | No | 2 | No | 6 | Yes | 6 | Yes |
| 4_203_08 | MDA | 8 | 3 | 5 | No | No | 3 | No | No | 1 | No | 2 | No | 3 | Yes |
| 6_175_07 | MDA | 9 | 4 | 5 | No | Yes | 5 | Yes | Yes | 3 | No | 4 | Yes | 4 | Yes |
| 6_319_05 | MDA | 8 | 3 | 5 | No | No | 3 | Yes | No | 3 | Yes | 4 | No | 3 | Yes |
| 6_537_08 | MDA | 8 | 3 | 5 | No | No | 3 | Yes | No | 2 | No | 3 | Yes | 3 | Yes |
| 2_005_03 | No MDA | 9 | 5 | 7 | No | No | 6 | Yes | No | 5 | Yes | 5 | Yes | 4 | No |
| 2_011_08 | No MDA | 8 | 6 | 5 | No | No | 6 | Yes | No | 3 | Yes | 6 | No | 7 | No |
| 2_052_05 | No MDA | 8 | 5 | 4 | No | Yes | 5 | No | No | 3 | No | 5 | Yes | 5 | Yes |
| 2_156_04 | No MDA | 7 | 7 | 5 | No | Yes | 6 | No | No | 2 | No | 6 | No | 7 | Yes |
| 2_177_06 | No MDA | 9 | 6 | 5 | No | No | 7 | No | No | 3 | No | 6 | Yes | 6 | Yes |
| 2_210_07 | No MDA | 8 | 6 | 6 | No | Yes | 5 | No | No | 2 | No | 6 | Yes | 6 | Yes |
| 2_222_05 | No MDA | 9 | 4 | 5 | No | No | 4 | Yes | No | 2 | No | 4 | Yes | 4 | Yes |
| 2_316_03 | No MDA | 8 | 6 | 7 | No | No | 5 | No | No | 3 | No | 6 | Yes | 5 | No |
| 2_427_07 | No MDA | 8 | 5 | 4 | No | Yes | 6 | No | No | 3 | No | 5 | No | 7 | No |
| 2_460_02 | No MDA | 9 | 4 | 4 | No | Yes | 4 | Yes | Yes | 3 | No | 4 | Yes | 5 | No |
| 2_474_04 | No MDA | 8 | 4 | 3 | No | No | 3 | No | Yes | 2 | No | 4 | Yes | 4 | Yes |
| 5_172_05 | No MDA | 6 | 4 | 3 | No | No | 4 | Yes | No | 1 | No | 4 | Yes | 4 | Yes |
| 5_366_08 | No MDA | 7 | 5 | 5 | No | Yes | 4 | No | No | 3 | No | 6 | No | 5 | Yes |
| 7_233_03 | No MDA | 8 | 5 | 5 | Yes | Yes | 5 | Yes | Yes | 1 | No | 4 | No | 6 | No |
| 8_415_05 | No-MDA | 8 | 2 | 3 | No | No | 2 | Yes | No | 2 | Yes | 3 | No | 2 | Yes |
Diversity is measured using phylogenomics, resistance gene profiles, virulence gene profiles, phylogroups, MLST, and serotype. Cladograms were used to determine the relationships in the resistance gene profiles and virulence gene profiles of isolates within a subject and the number of lineages within each subject. Lineages with similar distributions are those that comprise the same isolates across diversity measurements. Phylogroups, MLST, and serotype distributions are considered similar if they contain the same number of types as phylogenomic lineages.
Further details are provided in Table S3.
FIG 4Phylogenomic distribution of sequence types of isolates from select subjects. A cladogram of the phylogeny highlighting relative positions of genomes of isolates from selected subjects with MLST sequence types shown in colored blocks corresponding to the sequence type as shown in the legend. Selected example subjects highlight low diversity within time points but high diversity across time (subject 1_182_04), high diversity within and across time (3_475_03), intermediate diversity across time (4_203_08), and low diversity across time (8_415_05).
Summary of macrolide resistance gene presence by treatment group and time point
| Time point(s) | Treatment | No treatment | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Subject | % of isolates by time point (mo) | % (no. | Subject | % of isolates by time point (mo) | % (no. | |||||
| 1 | 2 | 3 | 1 | 2 | 3 | |||||
| No macrolide | 3_073_06 | 0 | 0 | 0 | 46.67 (7/15) | 2_052_05 | 0 | 0 | 0 | 40 (6/15) |
| 3_373_03 | 0 | 0 | 0 | 2_156_04 | 0 | 0 | 0 | |||
| 3_475_03 | 0 | 0 | 0 | 2_177_06 | 0 | 0 | 0 | |||
| 4_203_08 | 0 | 0 | 0 | 2_222_05 | 0 | 0 | 0 | |||
| 6_175_07 | 0 | 0 | 0 | 2_474_04 | 0 | 0 | 0 | |||
| 6_319_05 | 0 | 0 | 0 | 8_415_05 | 0 | 0 | 0 | |||
| 6_537_08 | 0 | 0 | 0 | |||||||
| Only in 3 mo | 1_176_05 | 0 | 0.5 | 1 | 13.33 (2/15) | 2_005_03 | 0 | 0.66 | 0 | 33.33 (5/15) |
| 1_182_04 | 0 | 0.66 | 0 | 2_011_08 | 0 | 0.66 | 0 | |||
| 2_210_07 | 0 | 0.33 | 0 | |||||||
| 5_366_08 | 0 | 0.66 | 0 | |||||||
| 7_233_03 | 0 | 0.66 | 0 | |||||||
| Only in 6 mo | 1_110_08 | 0 | 0 | 1 | 13.33 (2/15) | 2_316_03 | 0 | 0 | 0.66 | 13.33 (2/15) |
| 1_392_07 | 0 | 0 | 0.66 | 2_427_07 | 0 | 0 | 0.66 | |||
| Pre- and | 1_250_04 | 1 | 1 | 1 | 13.33 (2/15) | 2_460_02 | 0.66 | 0 | 1 | 6.67 (1/15) |
| 3_105_05 | 0.33 | 0.33 | 0.33 | |||||||
| 3 and 6 mo | 3_020_07 | 0 | 1 | 0.66 | 13.33 (2/15) | 0.00 | ||||
| 3_267_03 | 0 | 0.5 | 0.5 | |||||||
| Only baseline | 0.00 | 5_172_05 | 1 | 0 | 0 | 6.67 (1/15) | ||||
The proportion of isolates in which a macrolide resistance gene was identified is shown for each time point. Subjects are separated in to treatment groups and categorized based on the time points in which macrolide resistance genes were identified. Percentages reflect the proportion of subjects who fall into each macrolide resistance gene category within treatment groups.